{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:24:26Z","timestamp":1757618666029,"version":"3.44.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-025-02685-w","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:50:29Z","timestamp":1752137429000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prediction of health-related quality-of-life results after lung stereotactic body radiotherapy using dose-volume parameters from functional mapping on Gallium-68 perfusion PET\/CT"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7286-1350","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Lucia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Lamour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaux","family":"Geier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Bourbonne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Pinot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malik","family":"Nebbache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Blanc-B\u00e9guin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Hennebicq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u00eblle","family":"Mauguen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Kerleguer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Schick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Pradier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e9goire","family":"Le Gal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Yves","family":"Salaun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Bourhis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Yves","family":"Le Roux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"unstructured":"Research C. for DE and. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims. Accessed 31 Jan 2024.","key":"2685_CR1"},{"key":"2685_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3816\/CLC.2008.n.009","volume":"9","author":"D Cella","year":"2008","unstructured":"Cella D, Eton D, Hensing TA, Masters GA, Parasuraman B. Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer. Clin Lung Cancer. 2008;9:51\u20138.","journal-title":"Clin Lung Cancer"},{"key":"2685_CR3","doi-asserted-by":"publisher","first-page":"789456","DOI":"10.3389\/fpubh.2022.789456","volume":"10","author":"S Jalili","year":"2022","unstructured":"Jalili S, Ghasemi Shayan R. A comprehensive evaluation of Health-Related life quality assessment through head and neck, prostate, breast, lung, and skin Cancer in adults. Front Public Health. 2022;10:789456.","journal-title":"Front Public Health"},{"key":"2685_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1477-7525-2-4","volume":"2","author":"S Boini","year":"2004","unstructured":"Boini S, Brian\u00e7on S, Guillemin F, Galan P, Hercberg S. Impact of cancer occurrence on health-related quality of life: a longitudinal pre-post assessment. Health Qual Life Outcomes. 2004;2:4.","journal-title":"Health Qual Life Outcomes"},{"key":"2685_CR5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1046\/j.1524-4733.1999.24006.x","volume":"2","author":"GJ Wan","year":"1999","unstructured":"Wan GJ, Counte MA, Cella DF, Hernandez L, Deasy S, Shiomoto G. An analysis of the impact of demographic, clinical, and social factors on health-related quality of life. Value Health. 1999;2:308\u201318.","journal-title":"Value Health"},{"key":"2685_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.12788\/jcso.0010","volume":"12","author":"J Buzaglo","year":"2014","unstructured":"Buzaglo J, Gayer C, Mallick R, Charap E, Ferris A, Golant M, et al. Understanding the experience of living with non-small-cell lung cancer (NSCLC): a qualitative study. J Community Support Oncol. 2014;12:6\u201312.","journal-title":"J Community Support Oncol"},{"issue":"Suppl 4","key":"2685_CR7","doi-asserted-by":"publisher","first-page":"iv279","DOI":"10.1093\/annonc\/mdh939","volume":"15","author":"K Bjordal","year":"2004","unstructured":"Bjordal K. Impact of quality of life measurement in daily clinical practice. Ann Oncol. 2004;15(Suppl 4):iv279\u2013282.","journal-title":"Ann Oncol"},{"key":"2685_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1758834010395342","volume":"3","author":"D Osoba","year":"2011","unstructured":"Osoba D. Health-related quality of life and cancer clinical trials. Ther Adv Med Oncol. 2011;3:57\u201371.","journal-title":"Ther Adv Med Oncol"},{"key":"2685_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/2191-1991-3-15","volume":"3","author":"K Damm","year":"2013","unstructured":"Damm K, Roeske N, Jacob C. Health-related quality of life questionnaires in lung cancer trials: a systematic literature review. Health Econ Rev. 2013;3:15.","journal-title":"Health Econ Rev"},{"unstructured":"Commissioner O of the. Core Patient-Reported Outcomes in Cancer Clinical Trials. 2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/core-patient-reported-outcomes-cancer-clinical-trials. Accessed 31 Jan 2024.","key":"2685_CR10"},{"unstructured":"Appendix. 2 to the guideline on the evaluation of anticancer medicinal products in man.","key":"2685_CR11"},{"key":"2685_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.radonc.2016.08.021","volume":"121","author":"J-P Pignol","year":"2016","unstructured":"Pignol J-P, Truong P, Rakovitch E, Sattler MG, Whelan TJ, Olivotto IA. Ten years results of the Canadian breast intensity modulated radiation therapy (IMRT) randomized controlled trial. Radiother Oncol. 2016;121:414\u20139.","journal-title":"Radiother Oncol"},{"key":"2685_CR13","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1200\/JCO.2007.14.6647","volume":"26","author":"JA Langendijk","year":"2008","unstructured":"Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol. 2008;26:3770\u20136.","journal-title":"J Clin Oncol"},{"key":"2685_CR14","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.oraloncology.2011.05.012","volume":"47","author":"BLT Ramaekers","year":"2011","unstructured":"Ramaekers BLT, Joore MA, Grutters JPC, van den Ende P, de Jong J, Houben R, et al. The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy. Oral Oncol. 2011;47:768\u201374.","journal-title":"Oral Oncol"},{"key":"2685_CR15","doi-asserted-by":"publisher","first-page":"5816","DOI":"10.1200\/JCO.2009.23.7420","volume":"27","author":"B Movsas","year":"2009","unstructured":"Movsas B, Moughan J, Sarna L, Langer C, Werner-Wasik M, Nicolaou N, et al. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol. 2009;27:5816\u201322.","journal-title":"J Clin Oncol"},{"key":"2685_CR16","doi-asserted-by":"publisher","first-page":"20150172","DOI":"10.1259\/bjr.20150172","volume":"88","author":"JE Scaife","year":"2015","unstructured":"Scaife JE, Barnett GC, Noble DJ, Jena R, Thomas SJ, West CML, et al. Exploiting biological and physical determinants of radiotherapy toxicity to individualize treatment. Br J Radiol. 2015;88:20150172.","journal-title":"Br J Radiol"},{"key":"2685_CR17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.radonc.2018.09.019","volume":"131","author":"J van Diessen","year":"2019","unstructured":"van Diessen J, De Ruysscher D, Sonke J-J, Damen E, Sikorska K, Reymen B, et al. The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). Radiother Oncol. 2019;131:166\u201373.","journal-title":"Radiother Oncol"},{"key":"2685_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.radonc.2009.02.010","volume":"91","author":"M Pijls-Johannesma","year":"2009","unstructured":"Pijls-Johannesma M, Houben R, Boersma L, Grutters J, Seghers K, Lambin P, et al. High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL. Radiother Oncol. 2009;91:443\u20138.","journal-title":"Radiother Oncol"},{"key":"2685_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-019-0064-5","volume":"5","author":"D De Ruysscher","year":"2019","unstructured":"De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F. Radiotherapy toxicity. Nat Rev Dis Primers. 2019;5:13.","journal-title":"Nat Rev Dis Primers"},{"key":"2685_CR20","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3390\/cancers15061726","volume":"15","author":"F Lucia","year":"2023","unstructured":"Lucia F, Hamya M, Pinot F, Goasduff G, Blanc-B\u00e9guin F, Bourhis D, et al. A feasibility study of functional lung volume preservation during stereotactic body radiotherapy guided by Gallium-68 perfusion PET\/CT. Cancers. 2023;15:1726.","journal-title":"Cancers"},{"unstructured":"Lucia F, Bourhis D, Pinot F, Hamya M, Goasduff G, Blanc-B\u00e9guin F et al. Prediction of acute radiation-Induced lung toxicity after stereotactic body radiation therapy using Dose-Volume parameters from functional mapping on gallium 68 perfusion positron emission tomography\/computed tomography. Int J Radiat Oncol Biol Phys. 2023;:S0360-3016(23)08008-2.","key":"2685_CR21"},{"key":"2685_CR22","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jtho.2018.10.170","volume":"14","author":"S Adebahr","year":"2019","unstructured":"Adebahr S, Hechtner M, Schr\u00e4der N, Schimek-Jasch T, Kaier K, Duncker-Rohr V, et al. Early impact of pulmonary fractionated stereotactic body radiotherapy on quality of life:benefit for patients with low initial scores (STRIPE Trial). J Thorac Oncol. 2019;14:408\u201319.","journal-title":"J Thorac Oncol"},{"key":"2685_CR23","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.3390\/cancers15072166","volume":"15","author":"F Pinot","year":"2023","unstructured":"Pinot F, Bourhis D, Bourbonne V, Floch R, Mauguen M, Blanc-B\u00e9guin F, et al. New automated method for lung functional volumes delineation with lung perfusion PET\/CT imaging. Cancers (Basel). 2023;15:2166.","journal-title":"Cancers (Basel)"},{"key":"2685_CR24","first-page":"211","volume":"21","author":"GMM Videtic","year":"2013","unstructured":"Videtic GMM, Reddy CA, Sorenson L. A prospective study of quality of life including fatigue and pulmonary function after stereotactic body radiotherapy for medically inoperable early-stage lung cancer. Support Care Cancer. 2013;21:211\u20138.","journal-title":"Support Care Cancer"},{"key":"2685_CR25","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.lungcan.2015.06.019","volume":"89","author":"C Ferrero","year":"2015","unstructured":"Ferrero C, Badellino S, Filippi AR, Focaraccio L, Giaj Levra M, Levis M, et al. Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study. Lung Cancer. 2015;89:350\u20136.","journal-title":"Lung Cancer"},{"key":"2685_CR26","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1016\/j.ijrobp.2011.03.052","volume":"81","author":"J Widder","year":"2011","unstructured":"Widder J, Postmus D, Ubbels JF, Wiegman EM, Langendijk JA. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer. Int J Radiat Oncol Biol Phys. 2011;81:e291\u2013297.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2685_CR27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.radonc.2013.06.045","volume":"108","author":"S Jain","year":"2013","unstructured":"Jain S, Poon I, Soliman H, Keller B, Kim A, Lochray F, et al. Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11 days: a comparison of acute toxicity and quality of life. Radiother Oncol. 2013;108:320\u20135.","journal-title":"Radiother Oncol"},{"key":"2685_CR28","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1097\/JTO.0b013e318252cfef","volume":"7","author":"FJ Lagerwaard","year":"2012","unstructured":"Lagerwaard FJ, Aaronson NK, Gundy CM, Haasbeek CJA, Slotman BJ, Senan S. Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer. J Thorac Oncol. 2012;7:1148\u201354.","journal-title":"J Thorac Oncol"},{"key":"2685_CR29","doi-asserted-by":"publisher","first-page":"e365","DOI":"10.1016\/j.prro.2014.12.002","volume":"5","author":"D Mathieu","year":"2015","unstructured":"Mathieu D, Campeau M-P, Bahig H, Larriv\u00e9e S, Vu T, Lambert L, et al. Long-term quality of life in early-stage non-small cell lung cancer patients treated with robotic stereotactic ablative radiation therapy. Pract Radiat Oncol. 2015;5:e365\u2013373.","journal-title":"Pract Radiat Oncol"},{"key":"2685_CR30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.12788\/jcso.0087","volume":"12","author":"V Sun","year":"2014","unstructured":"Sun V, Kim JY, Williams AC, Raz DJ, Sampath S, Ferrell B. Quality of life and symptoms following stereotactic body radiotherapy in early-stage lung cancer patients. J Community Support Oncol. 2014;12:407\u201314.","journal-title":"J Community Support Oncol"},{"key":"2685_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13014-015-0405-9","volume":"10","author":"RJ Ubels","year":"2015","unstructured":"Ubels RJ, Mokhles S, Andrinopoulou ER, Braat C, van der Voort NC, Aluwini S, et al. Quality of life during 5 years after stereotactic radiotherapy in stage I non-small cell lung cancer. Radiat Oncol. 2015;10:98.","journal-title":"Radiat Oncol"},{"key":"2685_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.lungcan.2009.05.019","volume":"68","author":"T Schulte","year":"2010","unstructured":"Schulte T, Schniewind B, Walter J, Dohrmann P, K\u00fcchler T, Kurdow R. Age-related impairment of quality of life after lung resection for non-small cell lung cancer. Lung Cancer. 2010;68:115\u201320.","journal-title":"Lung Cancer"},{"key":"2685_CR33","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.ejcts.2010.08.046","volume":"39","author":"C Pompili","year":"2011","unstructured":"Pompili C, Brunelli A, Xium\u00e9 F, Refai M, Salati M, Sabbatini A. Predictors of postoperative decline in quality of life after major lung resections. Eur J Cardiothorac Surg. 2011;39:732\u20137.","journal-title":"Eur J Cardiothorac Surg"},{"key":"2685_CR34","doi-asserted-by":"publisher","first-page":"100815","DOI":"10.1016\/j.adro.2021.100815","volume":"6","author":"S Devpura","year":"2021","unstructured":"Devpura S, Feldman AM, Rusu SD, Mayyas E, Movsas A, Brown SL, et al. An analysis of clinical toxic effects and quality of life as a function of radiation dose and volume after lung stereotactic body radiation therapy. Adv Radiat Oncol. 2021;6:100815.","journal-title":"Adv Radiat Oncol"},{"key":"2685_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.radonc.2022.09.020","volume":"176","author":"L van der Weijst","year":"2022","unstructured":"van der Weijst L, Azria D, Berkovic P, Boisselier P, Briers E, Bultijnck R, et al. The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: results of the REQUITE study. Radiother Oncol. 2022;176:127\u201337.","journal-title":"Radiother Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02685-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-025-02685-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02685-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T03:24:25Z","timestamp":1757215465000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-025-02685-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2685"],"URL":"https:\/\/doi.org\/10.1186\/s13014-025-02685-w","relation":{},"ISSN":["1748-717X"],"issn-type":[{"type":"electronic","value":"1748-717X"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures were performed in accordance with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study design and exemption from informed consent were approved by the Institutional Review Board of Brest University Hospital.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The study was approved by the Nord Ouest IV Ethics Committee (ID RCB: 2021-002224-20) and registered in ClinicalTrial.gov registry (NCT04942275). Written informed consent was obtained from all participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No potential conflicts of interest financial were disclosed.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of conflicts of interest"}}],"article-number":"108"}}